Prosecution Insights
Last updated: April 19, 2026
Application No. 18/145,588

ANTIBODIES RECOGNIZING SORTILIN

Final Rejection §DP
Filed
Dec 22, 2022
Examiner
LI, RUIXIANG
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Prothena Biosciences Limited
OA Round
2 (Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
2y 10m
To Grant
78%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allow Rate
602 granted / 1015 resolved
-0.7% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
29 currently pending
Career history
1044
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
25.8%
-14.2% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
34.8%
-5.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1015 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Application, Amendments, and/or Claims Applicant's amendment filed on 03/02/2026 has been entered. Claims 153-154 and 174-203 are pending and currently under consideration. Withdrawn Objections and/or Rejections The rejections of claims 153 and 174-188 under 35 U.S.C. 101 and under 35 U.S.C. 112 (a) are withdrawn in view of Applicant’s argument. The rejections of claims 154 and 189-203 under 35 U.S.C. 112 (a) are withdrawn in view of Applicant’s argument. The rejections of claims 153-154, and 174-203 under 35 U.S.C. 112 (b) are withdrawn in view of amended claims. Information Disclosure Statement The information disclosure statement filed on 03/02/2026 has been considered by the Examiner and an initialed copy of the form PTO-1449 is attached to this communication. Claim Rejections[Symbol font/0xBE] Nonstatutory Obviousness-Type Double Patenting (i). Basis for nonstatutory double patenting: The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/ guidance/eTD-info-I.jsp. (ii). Claims 153-154 and 174-203 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 145-149 of copending Application No. 18/011,764. The basis for the rejection is set forth in the office action mailed on 12/02/2025. Applicant requests to hold the obviousness-type double patenting rejection in abeyance. Conclusion No claims are allowed. Advisory Information THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vanessa Ford, can be reached on (571) 272-0857. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197. /RUIXIANG LI/Primary Examiner, Art Unit 1646 March 20, 2026
Read full office action

Prosecution Timeline

Dec 22, 2022
Application Filed
Nov 28, 2025
Non-Final Rejection — §DP
Mar 02, 2026
Response Filed
Mar 20, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599645
POLYPEPTIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12599596
ANTI-TUMOR PHARMACEUTICAL COMPOSITION BASED ON IMMUNE CHECKPOINT BLOCKADE AND USE THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12589150
ANTIBODIES BINDING AXL
2y 5m to grant Granted Mar 31, 2026
Patent 12583921
TARGETED ANTI-SGLT1 AVIAN IGY ANTIBODIES AS TREATMENT OF PRE-DIABETES, TYPE 2 DIABETES AND GESTATIONAL DIABETES
2y 5m to grant Granted Mar 24, 2026
Patent 12577307
METHOD AND MEDICAMENT FOR TREATING CANCER UNRESPONSIVE TO PD-1/PD-L1 SIGNALING INHIBITOR
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
78%
With Interview (+19.0%)
2y 10m
Median Time to Grant
Moderate
PTA Risk
Based on 1015 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month